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Activated forms of different Rho family members (CDC42, Rac1, RhoA, RhoB, and RhoG) have been shown
to transform NIH 3T3 cells as well as contribute to Ras transformation. Rho family guanine nucleotide
exchange factors (GEFs) (also known as Dbl family proteins) that activate CDC42, Rac1, and RhoA also
demonstrate oncogenic potential. The faciogenital dysplasia gene product, FGD1, is a Dbl family member that
has recently been shown to function as a CDC42-specific GEF. Mutations within the FGD1 locus cosegregate
with faciogenital dysplasia, a multisystemic disorder resulting in extensive growth impairments throughout the
skeletal and urogenital systems. Here we demonstrate that FGD1 expression is sufficient to cause tumorigenic
transformation of NIH 3T3 fibroblasts. Although both FGD1 and constitutively activated CDC42 cooperated
with Raf and showed synergistic focus-forming activity, both quantitative and qualitative differences in their
functions were seen. FGD1 and CDC42 also activated common nuclear signaling pathways. However, whereas
both showed comparable activation of c-Jun, CDC42 showed stronger activation of serum response factor and
FGD1 was consistently a better activator of Elk-1. Although coexpression of FGD1 with specific inhibitors of
CDC42 function demonstrated the dependence of FGD1 signaling activity on CDC42 function, FGD1 signaling
activities were not always consistent with the direct or exclusive stimulation of CDC42 function. In summary,
FGD1 and CDC42 signaling and transformation are distinct, thus suggesting that FGD1 may be mediating
some of its biological activities through non-CDC42 targets.
The Rho subfamily of Ras-related GTPases (14 mammalian
members) controls multiple aspects of cell behavior, including
cytoskeletal rearrangement, nuclear signaling, and cell growth
(reviewed in reference 67). For example, CDC42 mediates the
induction of actin microspikes and filopodia by bradykinin (26,
33), whereas Rac1 is required for growth factor-induced mem-
brane ruffling and lamellipodia formation (47). In contrast,
RhoA regulates the formation of actin stress fibers (46). In
Swiss 3T3 cells, the assembly of these structures involves a
cascade in which CDC42 activates Rac1, which in turn acti-
vates RhoA (33). Rho family proteins also have demonstrated
roles in the regulation of gene expression as measured by (i)
the transcriptional activation of the serum response factor
(SRF) (19), (ii) activation of c-Jun NH2-terminal kinase (JNK)
and its downstream target c-Jun (10, 32, 35), (iii) activation of
the ternary complex factor protein Elk-1 (62), (iv) activation of
p38/Mpk2 (63), and (v) regulation of expression from the cy-
clin D1 promoter (55). Finally, there is growing evidence that
the deregulated expression of Rho family members has pro-
found effects on the proliferative potential of cells. Activated
derivatives of RhoA, RhoB, Rac1, and CDC42 cause onco-
genic transformation when expressed in rodent fibroblast cell
lines and may contribute to Ras-mediated malignant transfor-
mation (23, 39, 41, 42, 53, 67).
Rho family GTPases function as regulated switches that
cycle between a biologically active GTP-bound and an inactive
GDP-bound form (5). They are activated by guanine nucleo-
tide exchange factors (GEFs) that catalyze the exchange of
bound GDP for GTP and inactivated by GTPase-activating
proteins that stimulate GTP hydrolysis (4). The Dbl-related
proteins are a large family of structurally related molecules
that have a common ability to catalyze GEF activity for specific
members of the Rho family (7, 59). Like activated derivatives
of their putative GTPase targets, catalytically active derivatives
of many Dbl-related proteins are highly oncogenic, promoting
tumor growth in nude mice.
The region of sequence similarity that defines members of
the Dbl family consists of a Dbl homology (DH) domain ar-
ranged in tandem with a pleckstrin homology (PH) domain.
An intact DH domain is essential for the GEF activity of the
Dbl protein (the mammalian prototype of the Dbl family) as
well as for the transforming activity of many Dbl family pro-
teins (20, 31, 48, 57, 58, 60). The PH domain also mediates the
transforming activity of Dbl-related proteins, in part, by tar-
geting them to specific cellular locations (58, 65).
FGD1 was determined by positional cloning to be the gene
responsible for faciogenital dysplasia (FGDY) (also known as
Aarskog-Scott syndrome), an X-linked skeletal dysplasia first
described in 1970 (1). Mutations at the FGDY locus alter the
size and shape of a number of small bones and cartilage ele-
ments but leave other skeletal structures unaffected (15, 16).
The cardinal features of this disease include widely spaced eyes
(hypertelorism), ptosis, down-slanting palpebral fissures,
dysplastic ears, maxillary hypoplasia, and disproportionate ac-
romelic short stature; radiographic abnormalities include max-
illary and mandibular hypoplasia, hypoplastic phalanges, re-
tarded bone maturation, and a variety of vertebral anomalies
including cervical spina bifida occulta and odontoid hypoplasia
(15, 16). These observations suggest that, like the genes re-
sponsible for the mouse mutations short ear (25) and brachy-
podism (50), FGD1 acts on a limited number of mesenchymal
condensations during skeletogenesis (16).
The FGDY gene product (FGD1) encodes tandem DH and
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PH domains (38) and has been shown recently to encode GEF
activity specific for CDC42 (64). Microinjection of FGD1 into
Swiss 3T3 cells induces the formation of filopodial extensions
consistent with the in vivo activation of CDC42 (36). The
demonstrated relationship between FGD1 and CDC42 func-
tion suggests that they may have a common ability to regulate
signaling pathways that influence cell growth, cell cycle pro-
gression, and transcription.
Although CDC42 involvement in the regulation of cell mor-
phology and gene expression has been well documented (10,
19, 26, 33), its contribution, if any, to proliferative signaling
pathways remains unclear. The stable expression of the con-
stitutively activated, GTPase-defective CDC42(12V) mutant
has been shown to be growth inhibitory in NIH 3T3 cells (28)
yet growth promoting in Rat-1 cells (40). In contrast, a recent
report indicates that an NIH 3T3 cell line that has been stably
transfected with a second constitutively activated CDC42 mu-
tant [CDC42(F28L)] exhibits many of the hallmarks of trans-
formation (28). This suggests that constitutively activated mu-
tants of CDC42 do not have equivalent activities in biological
assays and that they do not necessarily mimic activation of
endogenous CDC42 by a GEF. The latter point is illustrated by
our recent observation that Dbl family members whose in vitro
exchange activities include CDC42 exhibit potent focus-form-
ing activity in NIH 3T3 cells whereas activated derivatives of
their putative GTPase targets do not ((56); unpublished ob-
servations). Thus, it is unclear whether FGD1 would regulate
signaling pathways leading to cell proliferation and transfor-
mation or pathways that trigger growth inhibition.
In the present study we have compared the abilities of acti-
vated derivatives of CDC42 and FGD1 to transform NIH 3T3
mouse fibroblasts and their abilities to stimulate the activation
of nuclear signaling pathways. NIH 3T3 cells were used in
these studies, because they are an embryonic fibroblast cell line
and our in situ analyses have revealed that the highest level of
FGD1 expression occurs during development in mesenchymal
condensations (unpublished observations). FGD1 expression is
first detected prior to the differentiation of chondrocytes and
osteoblasts, when mesenchymal condensations are comprised
almost exclusively of embryonic fibroblast cells (17). Whereas
both FGD1 and CDC42 can cause growth transformation of
NIH 3T3 cells, they do so in qualitatively and quantitatively
distinct manners. Similarly, both FGD1 and CDC42 exhibit
distinct signaling profiles when assayed for their ability to stim-
ulate the activation of nuclear signalling pathways mediated by
SRF, Elk-1, and c-Jun. Although the stimulation of these tran-
scriptional activities by FGD1 occurs in a CDC42-dependent
manner, they cannot always be attributed to direct or exclusive
stimulation of CDC42 function. In summary, our comparison
of CDC42 and FGD1 transforming and signaling activities
suggests that FGD1 may regulate some of these activities
through non-CDC42 targets.
MATERIALS AND METHODS
Molecular constructs. pRK5-myc-FGD1 (36) encodes the tandem DH and PH
domains of the FGD1 protein (residues 375 to 710) fused at the NH2 terminus
to a Myc epitope tag. pRK5-myc-FGD1D (36) encodes a naturally occurring
splice variant of FGD1 that contains a deletion within the DH domain; it encodes
a derivative with the same NH2 and COOH termini as pRK5-myc-FGD1 but is
missing residues 398 to 433 (37). pAX142-myc-FGD1 and pAX142-myc-FGD1D
were made by isolating the ScaI/EcoRI inserts from pRK5-myc-FGD1 and
pRK5-myc-FGD1D, respectively, filling in the ends of the fragments with T4
DNA polymerase, and ligating into pAX142 (58) digested with SmaI. pAX142-
lsc-D7HA (56) and pAX142-Dbl-HA1 (56) encode transforming derivatives of
the Lsc and Dbl proteins, respectively, fused in frame at the NH2 terminus to an
epitope from the hemagglutinin (HA) protein of influenza virus. The cDNA
sequences encoding wild-type Rac1 and RhoA, dominant-inhibitory RhoA
[RhoA(19N)], and dominant-inhibitory CDC42 [CDC42(17N)] were removed
from the pZIP-NeoSV(x)1 vector (24) and inserted into the SmaI site of
pAX142. pAX142-cdc42(12V) encodes a constitutively activated derivative of the
CDC42 protein (kindly provided by R. Cerione) inserted into the SmaI site of
pAX142. pcDNA3-HA-cdc42 encodes wild-type CDC42 protein fused at the
NH2 terminus to an HA epitope (kindly provided by S. Bagrodia and R. Ceri-
one). pZIP-raf(340D) (24) encodes a weakly transforming, activated derivative of
the Raf-1 kinase. pyDF30-WASP-GBD encodes the GTPase binding domain
(GBD) of WASP (the product of the Wiskott-Aldrich syndrome locus) and was
kindly provided by M. Symons (40). WASP was shown recently to be a CDC42-
specific effector (3, 52). The cDNA sequences encoding b-galactosidase were
removed from pcDNA3.1/His/lacZ (Invitrogen) and inserted into the SmaI site
of pAX142.
Cell culture, transfection, and transformation assays. NIH 3T3 cells were
maintained in Dulbecco’s modified Eagle medium (high glucose) supplemented
with 10% calf bovine serum. Primary focus formation assays were performed in
NIH 3T3 cells exactly as described previously (9). Briefly, NIH 3T3 cells were
transfected by calcium phosphate coprecipitation in conjunction with a glycerol
shock. Focus formation was scored at 14 days. Cognate empty vectors for each
construct were employed as controls. NIH 3T3 cell lines that stably express
pRK5, pRK5-myc-FGD1, and pRK5-myc-FGD1D were generated by calcium
phosphate coprecipitation followed by selection for 14 days in growth medium
supplemented with G418 (200 mg/ml). Multiple drug-resistant colonies (.100)
were pooled together to establish cell lines for the transformation assays. For
secondary focus assays 103 stably selected cells were mixed with 106 untrans-
fected NIH 3T3 cells and then plated on 60-mm-diameter dishes. Foci were
scored at 7 days. Anchorage-independent growth and tumorigenicity in nude
mice were measured as described previously (9, 34). For soft agar assays and
primary and secondary focus formation assays, experiments were performed in
triplicate.
Transient-expression reporter gene assays. For transient-expression reporter
assays, NIH 3T3 cells were transfected by calcium phosphate coprecipitation,
allowed to recover for 30 h, and starved in Dulbecco’s modified Eagle medium
with 0.5% newborn calf serum for 14 h before lysate preparation (9, 18, 54).
Analysis of luciferase expression in transiently transfected NIH 3T3 cells was
performed as previously described by using enhanced chemiluminescence re-
agents and a Monolight 2010 luminometer (Analytical Luminescence, San Di-
ego, Calif.) (18). The reporter constructs utilized have been described previously:
Gal4-Elk-1 (30) and 53Gal4-luc (51), Gal-Jun(1-223) (51), (SREm-)2Luc (55),
and CD1-Luc (2). b-Galactosidase activity in transiently transfected NIH 3T3
cells was determined exactly as described previously (29). All assays were per-
formed in triplicate.
Western blotting. Expression of Myc-epitope-tagged FGD1 proteins in tran-
siently transfected 293 cells and in stably selected NIH 3T3 cell lines was deter-
mined by Western blot analysis as described previously (58) by using the 9E10
antibody (Santa Cruz Biotech). Membranes were incubated with horseradish
peroxidase-labeled anti-mouse secondary antibodies, and protein was visualized
with enhanced chemiluminescence reagents (Amersham).
RESULTS
FGD1 and Raf cooperate to transform NIH 3T3 mouse fi-
broblasts. Although FGD1 expression alters the actin cytoskel-
eton in a manner consistent with the in vivo activation of
CDC42 (36), its role, if any, in the regulation of cell prolifer-
ation has not yet been determined. To investigate the role of
the FGD1 protein in the control of cell growth, we compared
the effects of expressing catalytically active derivatives of
FGD1 and CDC42 on the proliferative properties of NIH 3T3
mouse fibroblasts. During murine development FGD1 expres-
sion is first detected in cellular condensations that are com-
prised exclusively of fibroblasts (unpublished observations).
pAX142-myc-FGD1 encodes a fragment of the FGD1 protein
that exhibits in vitro GEF activity specific for the CDC42
protein (64) and induces the formation of filopodia when in-
jected into Swiss 3T3 cells (36). pAX142-cdc42(12V) encodes
an activated derivative of CDC42 that has been shown previ-
ously to be transforming in Rat-1 but not NIH 3T3 cells. To
assess the relationship between GEF and transforming activity,
we also examined the transforming properties of pAX142-myc-
FGD1D, which encodes a biologically inactive peptide derived
from a naturally occurring splice variant of the FGD1 protein
(37). FGD1D is identical to FGD1 except that it harbors a
small deletion (residues 398 to 433) within the DH domain.
Initially, we compared the abilities of FGD1, FGD1D, and
CDC42(12V) to induce the formation of foci in a primary focus
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formation assay. At DNA concentrations up to 5 mg/60-mm-
diameter plate, pAX142-cdc42(12V), pAX142-myc-FGD1, and
pAX142-myc-FGD1D failed to induce focus formation when
transfected into NIH 3T3 cells (Fig. 1a). In this respect, FGD1
differs from other Dbl family members that encode GEF ac-
tivity for CDC42, such as the Dbl and Dbs oncoproteins (56).
Activated derivatives of Dbl and Dbs exhibit potent transform-
ing activity in primary focus formation assays (56).
We and others have shown that activated derivatives of the
Dbl and Rho families can synergistically interact with activated
Raf-1 to induce potent focus formation in NIH 3T3 cells (22,
24, 41, 42). In addition, it has been shown that dominant-
inhibitory versions of CDC42, Rac1, RhoA, RhoB, and RhoG
can block the transforming activity of Ras (23, 27, 39–42, 49).
To further investigate the oncogenic potential of FGD1, we
compared the abilities of FGD1 and CDC42 to cooperate with
Raf-1 in an NIH 3T3 cell focus formation assay. For this
analysis we utilized a weakly activated derivative of Raf-1
[Raf(340D)] that has been shown previously to have very weak
activity in a focus formation assay (24). Whereas the expres-
sion of either FGD1 or Raf(340D) alone produced relatively
few foci, coexpression of FGD1 and Raf(340D) caused a .15-
fold enhancement of focus-forming activity (Fig. 1a). A much
weaker cooperativity (threefold) was observed when we coex-
pressed Raf(340D) with CDC42(12V), and no cooperativity
was observed between Raf(340D) and FGD1D or the empty
pRK5 vector control.
Interestingly, the morphology of the foci induced by Raf in
cooperation with FGD1 (Raf 1 FGD1-induced foci) was strik-
ingly different from the morphology of the Raf 1 CDC42-
induced foci (Fig. 1b). The Raf 1 FGD1-induced foci had a
swirled morphology, contained elongated and highly refractile
cells, and were indistinguishable in appearance from foci in-
duced by activated Raf or Ras alone (data not shown). In
contrast, Raf 1 CDC42-induced foci lacked refractile cells and
exhibited the more dense, stellate morphology reminiscent of
transformed foci induced by Rho and Dbl family proteins.
Based on the clear differences we observe between FGD1 and
CDC42 (both quantitative and qualitative) in these coopera-
tion assays, we conclude that either the cdc42(12V) mutation
does not precisely mimic activation of CDC42 by FGD1 or the
FGD1 protein has an in vivo signaling activity that is distinct
from CDC42 activation.
Stable expression of FGD1 in NIH 3T3 cells is sufficient to
cause anchorage independence and tumorigenic transforma-
tion. To further examine the effects of FGD1 expression on cell
growth, we established stable lines of NIH 3T3 cells that con-
stitutively express FGD1. NIH 3T3 cells were stably trans-
fected with pRK5-myc-FGD1, pRK5-myc-FGD1D, or the
empty pRK5 vector control, and then multiple G418-resistant
colonies were pooled. Numerous G418-resistant colonies were
FIG. 1. CDC42(12V) and FGD1 cooperate with Raf-1 in NIH 3T3 focus
formation assays. (a) NIH 3T3 cells were cotransfected with pZIP-NeoSV(x)1 or
pAX142 expression plasmids encoding the indicated proteins. Five hundred
nanograms of each construct was transfected per 60-mm-diameter dish. Foci of
transformed cells were counted at 14 days. Data shown are from one experiment
performed in duplicate and are representative of three independent experiments.
Error bars, standard errors. (b) FGD1 and CDC42(12V) cooperate with
Raf(340D) to cause transformed foci with distinct morphologic appearances.
Foci were photographed under phase microscopy at 14 days.
FIG. 2. FGD1 causes growth transformation of NIH 3T3 cells. NIH 3T3 cells
were transfected with 3 mg of pRK5 or pRK5-myc-FGD1 and then selected for
14 days with G418-containing growth medium (200 mg/ml). (a) Expression of
FGD1 and FGD1D. The upper panel shows FGD1 expression in a stably selected
NIH 3T3 cell line. The lower panel shows transient expression of FGD1 and
FGD1D in 293 cells. Expression was determined by Western blot analysis using
an anti-Myc antibody (9E10; Santa Cruz Biotech). (b) NIH 3T3 cells that con-
stitutively express FGD1 cause Rho-like transformed foci in a secondary focus
formation assay. Stably selected cells (103) were mixed with 106 untransformed
cells and then plated. Foci were counted and photographed at 7 days. (c) FGD1
promotes anchorage-independent growth in soft agar when constitutively ex-
pressed in NIH 3T3 cells. The FGD1-transfected cell line was seeded at 5 3 104
cells per 60-mm-diameter dish in growth medium containing 0.3% agar over a
base layer of 0.6%. Colonies were counted and photographed at 21 days.
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selected from FGD1-transfected cells, and we were able to
readily detect expression of FGD1 protein (Fig. 2A). In con-
trast, relatively few G418-resistant colonies were obtained
from the FGD1D-transfected cells and we were unable to se-
lect cell populations in which we could detect expression of the
protein. The failure to detect expression of FGD1D was not
due to inherent instability of the protein, since good expression
was observed in transiently transfected 293 cells (Fig. 2A). A
more likely explanation is that FGD1D is either toxic or growth
inhibitory when constitutively expressed in NIH 3T3 cells.
Although cell populations expressing FGD1 exhibited no
obvious morphological transformation compared to cells trans-
fected with vector alone (not shown), the FGD1-expressing
cell line exhibited significant secondary focus formation and
growth in soft agar (Table 1 and Fig. 2B and C). The focus
morphology associated with FGD1 expression (Fig. 2B) is typ-
ical of Dbl family members and is reminiscent of the focus
morphology that is associated with activated derivatives of
RhoA or Rac1 in NIH 3T3 cells (23). We also examined the
FGD1-expressing cells for tumorigenicity in nude mice. Cells
expressing FGD1 showed rapid tumor formation, while vector
control lines did not (Table 1). We conclude that the expres-
sion of a catalytically active derivative of FGD1 disrupts the
growth properties of NIH 3T3 fibroblasts and is sufficient for
tumorigenic transformation.
FGD1 and CDC42 show differing abilities to activate the
SRF, Elk-1, and c-Jun transcription factors. The distinct bio-
logical activities of FGD1 and CDC42 seen in the Raf coop-
erativity studies suggested that their signaling activities may
also be distinct. To address this question, we compared the
abilities of FGD1 and CDC42 to activate the c-Jun and Elk-1
transcription factors and to stimulate transcription from the
cyclin D1 promoter. We also compared their abilities to stim-
ulate transcription from a mutant serum response element
(from the c-fos promoter) that is only responsive to SRF acti-
vation. We have shown previously that Dbl family members
(including those with GEF activity for CDC42) have a common
ability to activate these four transcriptional reporters (56; un-
published observations).
Both FGD1 and CDC42(12V) stimulated transcription from
the SRF, c-Jun, and Gal-Elk reporters but showed negligible
activation of the cyclin D1 reporter (Fig. 3). Under identical
conditions, good activation of cyclin D1 transcription was ob-
served with an activated derivative of Dbl (Dbl-HA1), which is
in accordance with our previous observations (56). Although
FGD1 and FGD1D are expressed at equivalent levels when
transiently expressed (Fig. 2A), in no instance did we observe
signaling activity associated with FGD1D, thus indicating the
dependence of these signaling events on FGD1-encoded GEF
activity. Although both CDC42 and FGD1 stimulated the same
reporters, their relative degrees of activity differed for each
assay. Stimulation of SRF by CDC42 was consistently 10-fold
higher than that by FGD1, whereas both exhibited roughly
equivalent stimulation of c-Jun. In contrast, FGD1 consistently
stimulated higher levels of Elk-1 activity (threefold) than that
by CDC42. This suggests that the stimulation of these report-
ers by FGD1 and CDC42 may not be attributable to a common
mechanism of activation and again suggests that FGD1 may
encode biological activities that are not mimicked by the
CDC42(12V) mutant protein.
FGD1 cooperates with Raf(340D) to activate Elk-1 but not
SRF or c-Jun. The synergistic interaction that we have ob-
served between Raf(340D) and FGD1 in a primary focus for-
mation assay may be the consequence of cooperativity in the
activation of transcriptional pathways. c-Jun and Elk-1 are
activated by distinct mitogen-activated protein kinase cascades
FIG. 3. FGD1 and CDC42 stimulate transcription from common promoter
elements. NIH 3T3 cells were transfected with 1.5 mg of pAX142, pAX142-myc-
FGD1, pAX142-myc-FGD1D, or pAX142-cdc42(12V) along with luciferase gene
reporter constructs for SRF transcriptional activity (2.5 mg) (A), c-Jun transcrip-
tional activity (500 ng of Gal-Jun and 2.5 mg 53Gal) (B), Elk-1 transcriptional
activity (500 ng of Gal-Elk and 2.5 mg of 53Gal) (C), or cyclin-D1 transcription
(2.5 mg of CD1-luciferase) (D). Following transfection, cells were cultured for
30 h and then serum starved (0.5% calf serum) for 14 h before extract prepara-
tion. Luciferase activity was determined and expressed as fold activation relative
to the level of activation seen with the vector controls. Data shown are repre-
sentative of three independent experiments performed on duplicate plates. Error
bars, standard errors.







Vector 0.1 0.0 0/6
FGD1 6.8 0.2 5/6
a NIH 3T3 cells were transfected with 3 mg of pRK5-myc plasmid or pRK5-
myc-FGD1 and selected for 14 days with G418 (200 mg/ml). Protein expression
was determined by Western blotting using an anti-myc antibody (9E10; Santa
Cruz). Stably selected cells (103) were mixed with 106 untransfected cells and
then plated. Foci were scored at 7 days. Data are presented as the percentage of
transfected cells that gave rise to foci. Data shown are representative of three
independent assays done with duplicate plates.
b To assess colony formation in soft agar, each transfected cell line was seeded
at 5 3 104 cells per 60-mm-diameter dish in growth medium containing 0.3%
agar over a base layer of 0.6%. Colonies were counted at 21 days and expressed
as a percentage of plated cells. Data shown are representative of three indepen-
dent assays done in duplicate.
c Tumorigenic potential of the transfected cells was determined by subcuta-
neous inoculation into athymic nude mice (106 cells per site). For each cell line,
three mice (two sites per mouse) were inoculated. Data are presented as total
number of tumors per total number of sites. Mice that were negative for tumor
growth were monitored for 3 months before being sacrificed. freq, frequency.
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(e.g., JNK, p38, and extracellular signal-related kinase [ERK])
that have been implicated in the regulation of transforming
pathways in NIH 3T3 cells (reviewed in reference 67). In ad-
dition, we have shown previously that the activation of SRF-
mediated pathways correlates well with the transforming activ-
ity of Dbl family members and, in particular, those that have
GEF activity for CDC42 (56). To assess possible contributions
of SRF-, c-Jun-, and Elk-1-mediated pathways to FGD1 trans-
forming activity, we examined whether Raf(340D) cooperates
with FGD1 to activate these response elements.
Both activated CDC42 and FGD1 cooperated with Raf to
activate the Elk-1 responsive element (four- and threefold
above additive levels, respectively), but little or no cooperation
was observed in the SRF or c-Jun assays (Fig. 4). This suggests
that Elk-1-mediated signaling, but not that mediated by SRF
or c-Jun, may contribute to FGD1- and CDC42-mediated
transforming activity. However, since both FGD1 and CDC42
cooperate with Raf to activate Elk-1, this activation cannot
fully account for the qualitative and quantitative differences
that we have observed in CDC42 1 Raf and FGD1 1 Raf
focus assays. Even though the cooperation between FGD1 and
Raf in the Elk-1 assay is consistently higher than that between
CDC42 and Raf, it is unlikely that this marginal difference
(four- versus threefold) in activity can fully account for these
striking differences. We conclude that the differences in trans-
forming potency that we observed between FGD1 and CDC42
are attributable to the differential activation of additional sig-
naling pathways that we have not yet identified.
FGD1 activates Elk-1, SRF, and c-Jun via CDC42-regulated
pathways. Our observation that FGD1 and CDC42 have dif-
fering abilities to stimulate transcriptional and transforming
events suggests that not all FGD1 activity is mediated by its
interactions with CDC42. To explore this possibility further,
we wished to determine if FGD1 stimulation of transcription
from the Elk-1, c-Jun, and SRF reporters is impaired by coex-
pression with specific inhibitors of CDC42 function. pAX142-
cdc42(17N) encodes a GTPase-defective dominant-inhibitory
mutant of CDC42 (provided by R. Cerione). pyDF30-WASP-
GBD encodes the GBD of WASP (an effector protein specific
for CDC42) and has been shown to specifically inhibit CDC42-
and FGD1-mediated cytoskeletal rearrangements (36, 40, 52).
Coexpression of FGD1 with either WASP-GBD or CDC42
(17N) markedly inhibits its ability to activate SRF, Elk-1, or
c-Jun (Fig. 5). To test for possible toxicity of either WASP-
GBD or CDC42(17N), we cotransfected NIH 3T3 cells with
pAX142-b-galactosidase and either pyDF30-WASP-GBD or
pAX142-cdc42(17N). b-Galactosidase activity was equivalent
in cells transfected with pyDF30-WASP-GBD, with pAX142-
cdc42(17N), or with vector alone (data not shown), thus indi-
cating that WASP-GBD and CDC42(17N) do not kill NIH 3T3
FIG. 4. FGD1 and CDC42(12V) cooperate with Raf to stimulate Elk-1 but not SRF or c-Jun transcriptional activity. NIH 3T3 cells were cotransfected with pAX142
or pZIP-NeoSV(x)1 (500 ng) expression plasmids encoding the indicated proteins along with luciferase gene reporter constructs for SRF transcriptional activity (2.5
mg) (A), c-Jun transcriptional activity (500 ng of Gal-Jun and 2.5 mg of 53Gal) (B), or Elk-1 transcriptional activity (500 ng of Gal-Elk and 2.5 mg of 53Gal) (C).
Transcriptional assays were performed as described in the legend to Fig. 3. Data shown are representative of three independent experiments performed on duplicate
plates. Error bars, standard errors.
FIG. 5. FGD1 stimulates SRF, Elk-1, and c-Jun activity in a CDC42-dependent manner. NIH 3T3 cells were cotransfected with expression plasmids encoding the
indicated proteins (1.5 mg of pAX142, pAX142-myc-FGD1, pAX142-cdc42(12V), or pAX142-cdc42(17N); 0.25 mg of pyDF30 or pyDF30-WASP-GBD) along with
luciferase gene reporter constructs for SRF transcriptional activity (2.5 mg) (A), c-Jun transcriptional activity (500 ng of Gal-Jun and 2.5 mg of 53Gal) (B), or Elk-1
transcriptional activity (500 ng of Gal-Elk and 2.5 mg of 53Gal) (C). Transcriptional assays were performed as described in the legend to Fig. 3. Data shown are
representative of three independent experiments performed on duplicate plates. Error bars, standard error.
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cells in transient assays and that they do not inhibit expression
from the pAX142-encoded EF1-a promoter. Thus, we con-
clude that WASP-GBD and CDC42(17N) inhibition is specific
and that FGD1 activates c-Jun, Elk-1, and SRF via CDC42-
regulated pathways.
FGD1 activates Elk-1 and SRF but not c-Jun by direct
interaction with CDC42. We and others have shown that Ras
GEFs can stimulate the activity of wild-type Ras to activate
transcription from Ras-responsive promoter elements (8, 43,
44). To determine if FGD1 regulates transcriptional activation
via direct stimulation of CDC42, we measured FGD1 activa-
tion of the Elk-1, Jun, and SRF reporters in the presence of
wild-type CDC42. To more precisely measure cooperativity
due to synergy, we determined the titers of CDC42 and FGD1
DNA used in these transfections to a level (500 ng) at which
they exhibited low transcriptional activity when transfected
alone (Fig. 6a). Under these transfection conditions, we ob-
served that FGD1 acted synergistically with wild-type CDC42
to cause transcriptional activation of Elk-1 and SRF (3-fold
and 10-fold above additive levels, respectively) but not c-Jun
(Fig. 6a). Interestingly, a strongly transforming derivative of
Dbl that is consistently more active in Elk-1, c-Jun, and SRF
assays than FGD1 (Fig. 6a compares 50 ng of Dbl-HA1 to 500
ng of FGD1) failed to synergize with wild-type CDC42 in the
Elk-1 assays yet showed weak cooperativity in the c-Jun and
SRF assays. This suggests that Dbl family exchange factors
with equivalent in vitro substrates may interact with these
substrates, in vivo, in a biologically distinct manner. It further
suggests that activation of the JNK pathway by FGD1, al-
though clearly CDC42 dependent, may also require FGD1-
mediated signaling events that are independent of CDC42. A
plasmid construct encoding an activated derivative of Lsc, a
Dbl family protein with GEF activity for RhoA, but not
CDC42 (14, 60) failed to cooperate with wild-type CDC42 in
these signaling assays, thus indicating the specificity of the
synergy for CDC42 GEFs.
Finally, we wished to determine if FGD1 could cooperate
with Rho family GTPases other than CDC42 in signaling as-
says. We observed that under conditions under which FGD1
cooperated with CDC42 in SRF and Elk-1 assays, FGD1 did
not cooperate with wild-type Rac1 (Fig. 6b). Interestingly, co-
operativity was observed between FGD1 and wild-type RhoA
in the SRF assay (threefold above additivity) but not in the
c-Jun or Elk-1 assays. The cooperativity between FGD1 and
RhoA, although less striking than that between FGD1 and
CDC42, may reflect weak in vivo exchange activity of FGD1
for RhoA. In support of this we observed that FGD1-mediated
stimulation of transcription from the SRF and Elk-1 reporters
but not the c-Jun reporter is impaired by coexpression with
RhoA(19N), a dominant-inhibitory mutant of the RhoA pro-
tein (Fig. 7).
DISCUSSION
Disruption of the FGD1 locus by translocation or premature
truncation has been detected in patients that suffer from
FGDY (also referred to as Aarskog-Scott syndrome) (38).
Loss of the FGD1 locus is associated with a characteristic
pattern of growth impairment during development of the skel-
etal system, thus suggesting that FGD1-mediated signaling
pathways may play a crucial role in this process (1, 15, 16).
FGD1 is expressed during development in the embryonic fi-
FIG. 6. FGD1 cooperates with RhoA and CDC42 but not Rac1 to stimulate transcriptional response elements. NIH 3T3 cells were cotransfected with pAX142
expression plasmids encoding the indicated proteins (0.5 mg of pAX142, pAX142-cdc42, pAX142-FGD1, pAX142-lsc-D7HA, and pAX142-Dbl-HA1 [a] or 0.5 mg of
pAX142, pAX142-FGD1, pAX142-rhoA, pAX142-rac1, or pAX142-cdc42 [b]) along with luciferase gene reporter constructs for SRF transcriptional activity (2.5 mg)
(A), c-Jun transcriptional activity (500 ng of Gal-Jun and 2.5 mg of 53Gal) (B), or Elk-1 transcriptional activity (500 ng of Gal-Elk and 2.5 mg of 53Gal) (C).
Transcriptional assays were performed as described in the legend to Fig. 3. Data shown are representative of three independent experiments performed on duplicate
plates. Error bars, standard errors.
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broblasts that comprise the early mesenchymal condensations
(unpublished observations). Mesenchymal condensations form
by a variety of mechanisms, including increased mitotic activity
and the aggregation of cells towards a center (17). Our obser-
vation that FGD1 expression can disrupt the proliferative
properties of NIH 3T3 cells suggests that FGD1 may be a
necessary component of growth control pathways that regulate
the establishment of these condensations during normal em-
bryonic development. We have shown that expression of the
FGD1 gene product in NIH 3T3 cells is sufficient to cause
tumorigenic transformation as well as to activate transcription
factors (SRF, Elk-1, and c-Jun) which have demonstrated roles
in the regulation of cell growth. In addition, FGD1 synergizes
strongly with Raf in transformation assays. The synergy be-
tween FGD1 and Raf in transformation assays is associated
with an increase in Elk-1 but not SRF or c-Jun activation, thus
suggesting that activation of SRF or c-Jun is not necessary for
this synergistic interaction.
Whereas the transcriptional activation of c-Jun by FGD1 is
consistent with the previous observation that FGD1 is a good
stimulator of JNK activity (36, 64), it is unclear by which
mechanism FGD1 is stimulating Elk-1 activity. Elk-1 is a target
for the mitogen-activated protein kinases ERK (11, 12, 21),
JNK (6, 13, 61, 62, 66), and p38 (45, 62). It is unlikely that
FGD1 activation of Elk-1 is mediated by ERKs, since we and
others have observed that ERK1 and ERK2 are not activated
in COS cells by FGD1 (unpublished observations; 36). In ad-
dition, we have recently determined that Elk-1 can be activated
by many Dbl family members, most of which are not good
activators or ERKs (unpublished observations). It also appears
that FGD1-mediated Elk-1 activation is not a consequence of
JNK activation, since FGD1 cooperates with CDC42 and Raf
to activate Elk-1 under conditions where c-Jun (and presum-
ably JNK) activity remains unchanged. The components of the
pathway leading from FGD1/CDC42 to Elk-1 activation re-
main to be elucidated.
Although recent evidence suggests that FGD1 functions ex-
clusively as an activator of CDC42 (36, 64), the transforming
activity and signaling profile of FGD1 in the present study were
not always consistent with in vivo activation of CDC42. We
observed both qualitative and quantitative differences between
FGD1 and CDC42(12V) in transformation assays, and both
proteins exhibited distinctive patterns of activation of reporter
elements. One explanation for these differences is that FGD1
may be utilizing GTPase substrates other than CDC42 to trig-
ger downstream signaling events. In support of this, we ob-
served that FGD1 consistently exhibits cooperativity with wild-
type RhoA in SRF reporter assays and that a dominant-
inhibitory mutant of RhoA partially blocks signaling by FGD1.
Although this suggests that FGD1 may be utilizing RhoA as a
substrate in vivo, it is also possible that RhoA is acting down-
stream of CDC42 to regulate some of the FGD1 signaling
activities. We also observed that FGD1 does not cooperate
with wild-type CDC42 in an assay for c-Jun activation under
conditions under which a second CDC42 GEF (Dbl) does.
Thus, although FGD1 activates c-Jun in a CDC42-dependent
manner, this activation may be dependent upon additional
FGD1-mediated signaling activities. We have shown recently
that several Dbl family members have a broader range of in
vivo substrate utilization than is indicated by their in vitro
activity, and this may also apply to FGD1 (56).
Some of the differences we observed between CDC42 and
FGD1 in both signaling and transformation assays may also be
attributable to the inability of a constitutively activated mutant
to precisely mimic activation of a GTPase by a GEF. The
biological consequences of an interaction between an exchange
factor and a GTPase are likely to differ for each GEF, and
constitutively activated mutants of the GTPase may not always
be able to substitute for the GEF-GTPase complex. For exam-
ple, Dbl family GEFs may sequester their GTPase targets to
particular cellular locations and, consequently, regulate differ-
ential interactions with specific effectors. Thus, the GEF may
need to be present to optimize the stimulation of a particular
signaling pathway by the GTPase. If true, this would explain
how FGD1 can be a much more efficient activator of Elk-1
than CDC42(12V) yet still clearly activate Elk-1 in a CDC42-
dependent manner.
Additionally, it is possible that differences between FGD1
and CDC42 activity may be a phenomenon specific for the
cycling-defective CDC42(12V) mutant. Recent observations by
Lin et al. with the CDC42(28L) mutant suggest that enhanced
GDP/GTP cycling also contributes to downstream signaling
(28). However, our preliminary analysis of the CDC42(28L)
mutant indicates that it behaves identically to CDC42(12V) in
cooperativity focus formation assays with Raf(340D) (unpub-
lished observations), thus suggesting that the observed differ-
ences between CDC42 and FGD1 function cannot be simply
attributed to a lack of cycling by the CDC42(12V) mutant.
We have also examined the transforming and signaling ac-
tivities of FGD1D, a peptide derived from a naturally occurring
FIG. 7. FGD1 stimulates SRF and Elk-1 but not c-Jun activity in a RhoA-dependent manner. NIH 3T3 cells were cotransfected with expression plasmids encoding
the indicated proteins [1.5 mg of pAX142, pAX142-myc-FGD1, and pAX142-rhoA(19N)] along with luciferase gene reporter constructs for SRF transcriptional activity
(2.5 mg) (A), c-Jun transcriptional activity (500 ng of Gal-Jun and 2.5 mg of 53Gal) (B), or Elk-1 transcriptional activity (500 ng of Gal-Elk and 2.5 mg of 53Gal) (C).
Transcriptional assays were performed as described in the legend to Fig. 3. Data shown are representative of three independent experiments performed on duplicate
plates. Error bars, standard errors.
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splice variant of FGD1 that harbors a small deletion within its
DH domain (37). This deletion removes several residues that
are highly conserved in all DH domains and would be pre-
dicted to abolish the catalytic activity of FGD1 (59). Consistent
with this, we observed that FGD1D lacked any measurable
transforming or signaling activity when assayed under the same
conditions as FGD1. Interestingly, we were unable to select
stable cell lines that express detectable levels of the FGD1D
protein, suggesting that its expression may be toxic or growth
inhibitory to NIH 3T3 cells. Since we have also observed that
the dominant-negative CDC42(17N) mutant is also growth
inhibitory in NIH 3T3 cells (unpublished data), FGD1D may
form nonproductive interactions with CDC42 and thus may
represent a naturally occurring, dominant-inhibitory mutant of
FGD1.
In summary, we have presented evidence that expression of
the FGD1 protein has profound effects on growth control and
nuclear signaling activity in NIH 3T3 cells. Although we have
strong in vivo evidence that at least some of these events are
mediated by specific interactions between CDC42 and FGD1,
it is also clear that FGD1 has functions other than guanine
nucleotide exchange on CDC42. FGD1 expression is primarily
restricted to fetal and embryonic tissues (38), and recent RNA
in situ hybridizations show that FGD1 is predominantly ex-
pressed in cell populations from which skeletal precursors arise
(unpublished observations). Investigations as to whether
FGD1 and CDC42 exhibit a growth-promoting activity in skel-
etal precursors will be important to pursue. We are currently
evaluating whether FGD1 can promote the growth or differ-
entiation of osteoblasts.
ACKNOWLEDGMENTS
We thank Carol Martin and Que Lambert for technical support,
Jennifer Parrish for preparation of figures, Marc Symons for the
WASP-GBD cDNA sequences, and Rick Cerione for the cdc42(WT),
cdc42(17N), and cdc42(12V) cDNA sequences.
This work was supported by Public Health Service grants CA42978,
CA55008, and CA63071 to C.J.D. from the National Cancer Institute.
I.P.W. is a research fellow of the National Cancer Institute of Canada
supported with funds provided by the Terry Fox Run.
REFERENCES
1. Aarskog, D. 1970. A familial syndrome of short stature associated with facial
dysplasia and genital anomalies. J. Pediatr. 77:856–861.
2. Albanese, C., J. Johnson, G. Watanabe, N. Eklund, D. Vu, A. Arnold, and
R. G. Pestell. 1996. Transforming p21-Ras mutants and c-Ets-2 activate the
cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 270:
23589–23597.
3. Aspenström, P., U. Lindberg, and A. Hall. 1996. Two GTPases, Cdc42 and
Rac, bind directly to a protein implicated in the immunodeficiency disorder
Wiskott-Aldrich syndrome. Curr. Biol. 6:70–75.
4. Boguski, M. S., and F. McCormick. 1993. Proteins regulating Ras and its
relatives. Nature 366:643–654.
5. Bourne, H. R., D. A. Sanders, and F. McCormick. 1990. The GTPase super-
family: conserved structure and molecular mechanism. Nature 349:117–126.
6. Cavigelli, M., F. Dolfi, F.-X. Claret, and M. Karin. 1995. Induction of c-fos
expression through JNK-mediated TCF/Elk-1 phosphorylation. EMBO J.
14:5957–5964.
7. Cerione, R. A., and Y. Zheng. 1996. The Dbl family of oncogenes. Curr.
Opin. Cell Biol. 8:216–222.
8. Chevallier-Multon, M.-C., F. Schweighoffer, I. Barlat, N. Baudouy, I. Fath,
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